WHO Urges African Countries to Ramp up Readiness for COVID-19 Vaccination Drive


Thursday, November 26, 2020 / 6:10 PM / by World Health Organization / Header Image Credit: WHO 

Proshare Nigeria Pvt. Ltd.

As the race to find a safe and effective COVID-19 vaccine is showing increasing promise, a new World Health Organization (WHO) analysis finds that Africa is far from ready for what will be the continent's largest ever immunization drive.


All 47 countries in the WHO African Region have received WHO's Vaccine Readiness Assessment Tool which is intended to be used by Ministries of Health, with support from WHO and UNICEF. It provides a roadmap for countries to plan for COVID-19 vaccine introduction and covers 10 key areas: planning and coordination, resources and funding, vaccine regulations, service delivery, training and supervision, monitoring and evaluation, vaccine logistics, vaccine safety and surveillance and communications and community engagement.


Forty countries have updated the tool and provided data to WHO. An analysis finds that based on the self-reports by the countries, the African region has an average score of 33% readiness for a COVID-19 vaccine roll-out, which is well below the desired benchmark of 80%.


"The largest immunization drive in Africa's history is right around the corner, and African governments must urgently ramp up readiness. Planning and preparation will make or break this unprecedented endeavour, and we need active leadership and engagement from the highest levels of government with solid, comprehensive national coordination plans and systems put in place," said Dr Matshidiso Moeti, WHO Regional Director for Africa.


WHO together with Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovation and other partners is working to ensure equitable access to vaccines in Africa through the COVAX facility, the vaccines pillar of the WHO Access to COVID-19 Tools Accelerator. When vaccines are licensed and approved, COVAX will work to secure enough doses to provide protection to an initial 20% of the African population.


However, the WHO analysis of the country readiness data finds only 49% have identified the priority populations for vaccination and have plans in place to reach them, and 44% have coordination structures in place. Only 24% have adequate plans for resources and funding, 17% have data collection and monitoring tools ready and just 12% have plans to communicate with communities to build trust and drive demand for immunization.


"Developing a safe and effective vaccine is just the first step in a successful rollout," said Dr Moeti. "If communities are not onboard and convinced that a vaccine will protect their health, we will make little headway. It's critical that countries reach out to communities and hear their concerns and give them a voice in the process".


WHO estimates the cost of rolling out a COVID-19 vaccine on the African continent to priority populations will be around US$ 5.7 billion. This does not include an additional 15% - 20% cost for injection materials and the delivery of vaccines, which require trained health workers, supply chain and logistics and community mobilization. This cost is based on COVAX facility estimates of the average vaccine price at US$ 10.55 per dose and that a two-dose regimen will be needed.


WHO and partners recently released guidance on COVID-19 vaccination planning and deployment for national governments, aiming to help them design strategies for the deployment, implementation and monitoring of COVID-19 vaccines and better integrate their strategies and financing to boost efficiency.


Dr Moeti spoke during a virtual press conference today facilitated by APO Group. She was joined by Professor Helen Rees, Executive Director, Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, Chairperson, African Regional Immunization Technical Advisory Group (RITAG) and Chairperson of the South African Health Products Regulatory Authority. Other speakers were Professor Pontiano Kaleebu, Director Uganda Virus Research Institute (UVRI) and MRC/UVRI and London School of Hygiene and Tropical Medicine Uganda Research Unit; and Professor Fredrick N Were, Perinatal & Neonatal Medicine, University of Nairobi and Chief Research Scientist, Kenya Paediatric Research Consortium.

Proshare Nigeria Pvt. Ltd.


Related News

  1. May and Baker Launches Malact to Combat Malaria
  2. Ecobank Nigeria Holds Awareness Webinar on Diabetes
  3. A Positive View on Africa pre-Pfizer
  4. Lagos Calls for Precautions Against Second Wave of COVID-19
  5. COVID-19: WHO Urged Countries to Take Stronger Action to Stop Spread of Harmful Information
  6. Nigeria's Plans to Accelerate Investments in Production of Health Products
  7. DFS Africa To Launch Initiative To Ease COVID-19 Supply Chain Challenges
  8. COVID-19-Related Trafficking of Medical Products as a Threat to Public Health
  9. FG Lifts Ban on Interstate Travels; Re-opens Schools for Students in Graduating Classes
  10. Nnamdi Okafor MD, May and Baker To Speak On WebTV Market Review Tomorrow
  11. Matthew Azoji , MD Of Neimeth Pharmaceutical To Speak Tomorrow On WebTV
  12. Presidential Task Force Issues Revised Quarantine Protocol for Persons Arriving in Nigeria
  13. Dr. Debo Odulana to Speak On Health Tech and Research On WebTV Tomorrow
  14. CACOVID - Update on Activities and Phase 2 Rollout Plan
  15. OLAM Group Contributes N1 billion to the CACOVID Relief Fund, State Governments, NCDC and NIMR
  16. Ahead of Tomorrow on WebTV: Discussions on Investing In Healthcare Tech And Research In Nigeria
  17. FSDH Webinar: Sanwo-olu, El-Rufai, Obaseki Speak On COVID-19 Pandemic and Local Realities
  18. Innovate to Overcome: Financing Health Systems Against NCDs
  19. Ahead of Tomorrow on WebTV: Discussions on COVID-19: Assessment of the Infectious Disease Bill
  20. LASG Issues Eleventh Update on Coronavirus Situation in Lagos State As At May 09, 2020

Proshare Nigeria Pvt. Ltd.

Proshare Nigeria Pvt. Ltd.

Related News